Filing Flows › Arbutus Biopharma (ABUS) › Takeover & LBO
Is Arbutus Biopharma (ABUS) a takeover target?
A leveraged buyout does not work for Arbutus Biopharma on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-10-05): Roivant Sciences Ltd. (19.5%): On August 24, 2026, the Issuer commenced a modified Dutch auction tender offer to purchase for cancellation up to US$230 million in value of its Common Shares at prices between US$5.00 and US$5.75 per Common Share (the ".
Why a leveraged buyout does not fit
The buyout model needs Arbutus Biopharma's revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-10-05 · 13D · Roivant Sciences Ltd. (19.5%): On August 24, 2026, the Issuer commenced a modified Dutch auction tender offer to purchase for cancellation up to US$230 million in value of its Common Shares at prices between US$5.00 and US$5.75 per Common Share (the "
Arbutus Biopharma's latest quarter
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Questions
Is Arbutus Biopharma being acquired?
The latest signal on file is from 2026-10-05: Roivant Sciences Ltd. (19.5%): On August 24, 2026, the Issuer commenced a modified Dutch auction tender offer to purchase for cancellation up to US$230 million in value of its Common Shares at prices between US$5.00 and US$5.75 per Common Share (the ". A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Arbutus Biopharma?
A leveraged buyout does not work for Arbutus Biopharma on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.